跳到正文
原文
Biotechnology Innovation Organization· @IAmBiotech · X·· 26 天前AI 评分18
AI 导读

药品定价政策对试图获得治疗的患者究竟意味着什么? Apteka 创始人兼董事总经理 Jennifer Snow 与 @LupusOrg 宣传与政府关系高级副总裁 Pat Wildman 与 BIO 患者倡导高级总监 Karin Hoelzer 一起,就 IRA、PDABs 和“最惠国”(MFN)定价实践对试图获得治疗的患者究竟意味着什么进行了对话。#BIOPACE26

正文

What do drug pricing policies actually mean for patients trying to get treatment?

Jennifer Snow, Founder and Managing Director of Apteka and Pat Wildman, Senior Vice President, Advocacy & Government Relations at @LupusOrg joined BIO Senior Director of Patient Advocacy Karin Hoelzer for a conversation on what the IRA, PDABs, and Most Favored Nation (MFN) pricing practices actually mean for patients trying to get treatment. #BIOPACE26

来源:Biotechnology Innovation Organization · x.com